Winterlight Labs participants in a J&J Feasibility Study

TORONTO, January 5, 2017

Winterlight Labs, has entered into a agreement to participate in a feasibility study with Janssen R&D, a subsidiary of Johnson & Johnson, to assess the performance of its algorithms on speech samples collected in Janssen R&D clinical trials.

Leveraging AI to Predict Neurodegenerative Diseases - Johnson & Johnson Innovation facilitated an exclusive feasibility study between Janssen Research & Development, LLC and Winterlight Labs, Inc., a JLABS @ Toronto-based company. The research will evaluate Winterlight's proprietary technology for analyzing voice samples obtained from Janssen Research & Development's ongoing clinical trials in Alzheimer's and neurodegenerative diseases. The goal is to non-invasively predict dementia and neurodegenerative diseases long before clinical symptoms become apparent.

Read press release

About Winterlight Labs

Winterlight Labs is commercializing a proprietary language-based diagnostic system that analyzes natural speech to detect and monitor dementia, Alzheimer’s, aphasia, and various other cognitive conditions. Winterlight's scalable platform uses short recorded speech samples to analyze hundreds of linguistic cues, and can detect dementia and other conditions with a high level of accuracy. This is a major improvement over current pencil-and-paper tests which are time-consuming, costly, and difficult to administer. The platform has applications in drug trials, long-term and primary care, and speech-language pathology.

Since its founding, Winterlight Labs has seen strong interest from pharmaceutical companies and other potential partners who view the technology as a major improvement over current methods of detection or screening. The company has gained support from the pan-Canadian AGE-WELL Network of Centres of Excellence (NCE), the Ontario Brain Institute, Ontario Centres of Excellence, and the University of Toronto Banting and Best Centre for Innovation and Entrepreneurship. For more information, visit

Media Inquiries:
Winterlight Labs
Liam Kaufman, CEO
liam [at]